AstraZeneca (AZN) and Daiichi Sankyo's datopotamab deruxtecan has been recommended for approval in the EU to treat people with breast cancer, the companies said Friday.
The positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency was based on results from a phase 3 trial, the companies said, adding the recommendation will now be reviewed by the European Commission.
The phase 3 trial showed the drug decreased the risk of disease progression or death by 37% compared with chemotherapy, the companies said. The drug is approved in the US and Japan for the same patient population, they said.
Datopotamab deruxtecan, which was discovered by Daiichi Sankyo, is being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca, the companies said.
Price: 70.82, Change: -0.42, Percent Change: -0.59
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。